FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Scientific Reports Année : 2016

FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells

Résumé

Proteins involved in genetic stability maintenance and safeguarding DNA replication act not only against cancer initiation but could also play a major role in sustaining cancer progression. Here, we report that the FANC pathway is highly expressed in metastatic melanoma harboring the oncogenic microphthalmia-associated transcription factor (MiTF). We show that MiTF downregulation in melanoma cells lowers the expression of several FANC genes and proteins. Moreover, we observe that, similarly to the consequence of MiTF downregulation, FANC pathway silencing alters proliferation, migration and senescence of human melanoma cells. We demonstrate that the FANC pathway acts downstream MiTF and establish the existence of an epistatic relationship between MiTF and the FANC pathway. Our findings point to a central role of the FANC pathway in cellular and chromosomal resistance to both DNA damage and targeted therapies in melanoma cells. Thus, the FANC pathway is a promising new therapeutic target in melanoma treatment.

Domaines

Cancer
Fichier principal
Vignette du fichier
srep36539.pdf (3.8 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

inserm-02530529 , version 1 (03-04-2020)

Identifiants

Citer

Julie Bourseguin, Caroline Bonet, Emilie Renaud, Charlotte Pandiani, Marina Boncompagni, et al.. FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. Scientific Reports, 2016, 6, pp.36539. ⟨10.1038/srep36539⟩. ⟨inserm-02530529⟩
70 Consultations
58 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More